Presbyopia Cure Research progress: An Educational Article and expert Opinion

Presbyopia, commonly known as "old man's eye disease," is a condition that leads to difficulty seeing near objects due to changes in the eye's lens. Historical explanations date back to Aristotle, with significant contributions from figures like René Descartes and Ernst Brücke, who helped identify the ciliary muscle's role in accommodation. Benjamin Franklin devised the first bifocals in the 1780s as a solution for presbyopia. In the 19th century, advancements included the development of eye charts by Heinrich Kuechler and Eduard Jaeger for assessing near vision. Hermann von Helmholtz later explained that presbyopia results from the loss of lens elasticity due to aging. Presbyopia, an age-related decline in near vision, has driven the search for effective and convenient pharmaceutical therapies. Topical parasympathomimetic agents, particularly pilocarpine, have emerged as promising treatments for this condition. The aim of this paper is to provide an understanding and an overview of presbyopia research progress. Pilocarpine has been shown to effectively improve near vision in presbyopic patients. Early studies demonstrated its potential for inducing accommodative changes in the lens. Subsequent research confirmed that pilocarpine combined with diclofenac or phenylephrine can enhance near vision while maintaining distance vision and minimizing side effects. More recent studies affirmed that pilocarpine 0.4% improves near vision with a good safety profile. Additionally, investigations into lipoic acid choline ester suggest new avenues for improving lens elasticity and treating presbyopia. Conclusion: Topical pharmacologic treatments, especially those involving pilocarpine, represent a significant advancement in managing presbyopia. Current evidence supports the effectiveness of these therapies in improving near vision without severely affecting distance vision. The combination of pilocarpine with other agents like diclofenac or phenylephrine has demonstrated both efficacy and safety. Ongoing research into new compounds and formulations, such as lipoic acid, holds promise for future developments in presbyopia treatment. Further studies are needed to refine these therapies, address side effects, and optimize treatment protocols.